Jose M Silva, PhD
img_Jose M Silva
ASSOCIATE PROFESSOR | Pathology, Molecular and Cell Based Medicine
ASSOCIATE PROFESSOR | Oncological Sciences
Research Topics
Cancer, Cancer Genetics, Tumorigenesis
Multi-Disciplinary Training Area
Cancer Biology [CAB]
Research Interest
Unprecedented amount of information has been gathered regarding cancer genomes. However, our ability to identify functions that are critical only for cancer cells is still limited. We have successfully pioneered the integration of the state-of-the-art genomics, functional studies and system biology methods to generate functional maps. This integrative analysis pinpoints key regulatory hubs that when perturbed compromise cancer cell viability. My research is an ambitious and systematic program that start from the identification of the regulatory networks of cancer cells, it continues with in depth molecular characterization of the hubs involved in their homeostasis and it finishes with the translation of our discoveries to the clinic. Our research has generated 15 peer-review publications in the last three years (primary research and collaborations) including high profile journals such as Cell, Nature, Cancer Cell and Genes & Dev. Furthermore, our comprehensive studies have initiated one clinical trial (NCT02066532) and another one is on the way. The specific interest of my group is normal mammary development, breast tumorigenesis and therapeutics. For the near future, we will expand our findings of RSF1, BIN3 and miR-424/503 as novel breast cancer genes (Cell-2014, Genes & Dev.-2014, MCB-2014, Cancer Cell-under review) as well as the evaluation of STAT3 and HDAC6 inhibition as novel targeted therapies (Genes & Dev-2015 and Cancer Res.-under review). In the farther future, we will follow up our recent studies identifying novel targets for triple negative breast cancers and investigating mechanistically the intersection of aging and cancer.
Research Open Positions
Updated October-2015 -We are looking for a molecular cell biologist with experience in breast cancer research. Previous experience in genetic manipulation of cellular models, basic biochemistry and mouse models of breast cancer will be beneficial. -Applicants must have shown research abilities and capabilities to perform collaborative project within a team, and possess good written and verbal communication skills in English. Applicants must have a Ph.D. and evidence of research productivity. Please send your C.V., contact information for two references, and a brief motivation letter including a summary of research experience to: Jose M. Silva;

BSc, Complutense University of Madrid, Spain

PhD, Autonoma University of Madrid, Spain

PostDoc, Cold Spring Harbor Laboratory, NY

Senior Fellow, Cold Spring Harbor Laboratory, NY

Assistant Professor of Pathology, Columbia University Medical School

Adjunct Faculty, Columbia University Medical School

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Silva did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.